Funds by Charlemagne Capital

Fund & Sector
1 Month Perf.
1 Year Perf.
3 Year Perf.
5 Year Perf.
OCF
Charlemagne Magna New Frontrs
FO Equity - Emerging Markets
View Factsheet
2.5%
-
44.1%
-
56.3%
-
91%
-
3.51%
Charlemagne Magna Latin Am
FO Equity - Latin America
View Factsheet
-0.7%
-
41.5%
-
-7.2%
-
-7.6%
-
1.6%
Charlemagne Magna EmgMkDv
FO Equity - Emerging Markets
View Factsheet
0.5%
-
34.3%
-
15.2%
-
44.3%
-
1.4%
Charlemagne Magna Eastn Eurpn
FO Equity - Emerging Europe
View Factsheet
2.6%
-
34%
-
-15.4%
-
1.1%
-
2.86%
Charlemagne Magna Gbl Emg Mkt
FO Equity - Emerging Markets
View Factsheet
1.8%
68 / 264
18.4%
94 / 258
16.3%
43 / 207
35%
35 / 157
2.87%
Charlemagne MagnaBiphrm
FO Equity - Pharma Health & Biotech
View Factsheet
2.7%
10 / 32
14.8%
5 / 31
-
-
-
-
3.28%
Charlemagne OCCO Eastn Eurpn
FO Hedge/Stru Prod - Equity
View Factsheet
1.9%
14 / 120
11.2%
8 / 106
14.9%
23 / 75
38.5%
11 / 53
-
Charlemagne Magna MENA
FO Equity - MENA
View Factsheet
-1.6%
10 / 14
-2%
3 / 14
70.3%
1 / 13
143.5%
1 / 12
2.21%
Charlemagne Magna Africa
FO Equity - Emerging Markets
View Factsheet
0.8%
149 / 264
-4%
243 / 258
2.6%
94 / 207
21.9%
75 / 157
2.37%
Data provided by

The Content is only for your general information and use and is not intended to address your particular requirements. The Content does not constitute any form of advice, recommendation or arrangement by Moneywise and is not intended to be relied upon by you in making (or refraining from making) any specific investment or other decisions. Appropriate independent advice should be obtained before making any such decision.

This information is sourced from our partner Financial Express. We believe the data to be correct however you should take care in using any information.

You should be aware that prices may fall as well as rise and that the income derived can go down as well as up. When buying or selling any investment that fluctuates in price or value you may get back less than you invested. Past performance is not necessarily a guide to future performance.